References of "Castermans, Karolien"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.
Halkein, Julie ULg; Tabruyn, Sebastien P.; Ricke-Hoch, Melanie et al

in Journal of Clinical Investigation (2013), 123(5), 2143-54

Peripartum cardiomyopathy (PPCM) is a life-threatening pregnancy-associated cardiomyopathy in previously healthy women. Although PPCM is driven in part by the 16-kDa N-terminal prolactin fragment (16K PRL ... [more ▼]

Peripartum cardiomyopathy (PPCM) is a life-threatening pregnancy-associated cardiomyopathy in previously healthy women. Although PPCM is driven in part by the 16-kDa N-terminal prolactin fragment (16K PRL), the underlying molecular mechanisms are poorly understood. We found that 16K PRL induced microRNA-146a (miR-146a) expression in ECs, which attenuated angiogenesis through downregulation of NRAS. 16K PRL stimulated the release of miR-146a-loaded exosomes from ECs. The exosomes were absorbed by cardiomyocytes, increasing miR-146a levels, which resulted in a subsequent decrease in metabolic activity and decreased expression of Erbb4, Notch1, and Irak1. Mice with cardiomyocyte-restricted Stat3 knockout (CKO mice) exhibited a PPCM-like phenotype and displayed increased cardiac miR-146a expression with coincident downregulation of Erbb4, Nras, Notch1, and Irak1. Blocking miR-146a with locked nucleic acids or antago-miRs attenuated PPCM in CKO mice without interrupting full-length prolactin signaling, as indicated by normal nursing activities. Finally, miR-146a was elevated in the plasma and hearts of PPCM patients, but not in patients with dilated cardiomyopathy. These results demonstrate that miR-146a is a downstream-mediator of 16K PRL that could potentially serve as a biomarker and therapeutic target for PPCM. [less ▲]

Detailed reference viewed: 69 (26 ULg)
Peer Reviewed
See detailMicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy
Halkein, Julie ULg; Tabruyn, Sébastien ULg; Haghikia, Arash et al

Poster (2012, April)

Detailed reference viewed: 39 (1 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Tabruyn, Sébastien ULg; Haghikia, Arash et al

Poster (2012, January)

Detailed reference viewed: 36 (0 ULg)
Full Text
Peer Reviewed
See detailThe Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation
Nguyen, Ngoc-Quynh-Nhu ULg; Castermans, Karolien; Berndt, Sarah et al

in PLoS ONE (2011), 6(11), 27318-27318

Background: Angiogenesis, the formation of new blood vessels from existing vasculature, plays an essential role in tumor growth, invasion, and metastasis. 16K hPRL, the antiangiogenic 16-kDa N-terminal ... [more ▼]

Background: Angiogenesis, the formation of new blood vessels from existing vasculature, plays an essential role in tumor growth, invasion, and metastasis. 16K hPRL, the antiangiogenic 16-kDa N-terminal fragment of human prolactin was shown to prevent tumor growth and metastasis by modifying tumor vessel morphology. Methodology/Principal Findings: Here we investigated the effect of 16K hPRL on tumor vessel maturation and on the related signaling pathways. We show that 16K hPRL treatment leads, in a murine B16-F10 tumor model, to a dysfunctional tumor vasculature with reduced pericyte coverage, and disruption of the PDGF-B/PDGFR-B, Ang/Tie2, and Delta/Notch pathways. In an aortic ring assay, 16K hPRL impairs endothelial cell and pericyte outgrowth from the vascular ring. In addition, 16K hPRL prevents pericyte migration to endothelial cells. This event was independent of a direct inhibitory effect of 16K hPRL on pericyte viability, proliferation, or migration. In endothelial cell-pericyte cocultures, we found 16K hPRL to disturb Notch signaling. Conclusions/Significance: Taken together, our data show that 16K hPRL impairs functional tumor neovascularization by inhibiting vessel maturation and for the first time that an endogenous antiangiogenic agent disturbs Notch signaling. These findings provide new insights into the mechanisms of 16K hPRL action and highlight its potential for use in anticancer therapy. [less ▲]

Detailed reference viewed: 86 (20 ULg)
Peer Reviewed
See detailThe antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation
Nguyen, Ngoc-Quynh-Nhu ULg; Castermans, Karolien; Berndt, Sarah et al

Poster (2011, May)

16K hPRL, the antiangiogenic 16-kDa N-terminal fragment of human prolactin was shown to prevent tumor growth and metastasis by modifying tumor vessel morphology. Here we investigated the effect of 16K ... [more ▼]

16K hPRL, the antiangiogenic 16-kDa N-terminal fragment of human prolactin was shown to prevent tumor growth and metastasis by modifying tumor vessel morphology. Here we investigated the effect of 16K hPRL on tumor vessel maturation and on the related signaling pathways. We show that 16K hPRL treatment leads, in a murine B16-F10 tumor model, to a dysfunctional tumor vasculature with reduced pericyte coverage, and disruption of the PDGF-B/PDGFR-B, Ang/Tie2, and Delta/Notch pathways. In an aortic ring assay, 16K hPRL impairs endothelial cell and pericyte outgrowth from the vascular ring. In addition, 16K hPRL prevents pericyte migration to endothelial cells. This event was independent of a direct inhibitory effect of 16K hPRL on pericyte viability, proliferation, or migration. In endothelial cell-pericyte cocultures, we found 16K hPRL to disturb Notch signaling, this being the first time such an effect is observed with an endogenous antiangiogenic agent. These findings provide new insights into the mechanisms of 16K hPRL action and highlight its potential for use in anticancer therapy. [less ▲]

Detailed reference viewed: 30 (5 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, March)

Detailed reference viewed: 8 (2 ULg)
Peer Reviewed
See detailMir-146a : A new angiostatic miRNA with tumor-suppressive properties
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, March)

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, February)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailMiR-146a: an angiostatic miRNA with tumor-suppressive properties
Halkein, Julie ULg; Bovy, Nicolas ULg; Castermans, Karolien et al

Poster (2011, February)

Detailed reference viewed: 10 (2 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, January)

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailMir-146a : A new angiostatic miRNA with tumor-suppressive properties
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2010, October)

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detail16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo
Kinet, Virginie; Castermans, Karolien; Blacher, Silvia ULg et al

Poster (2010, May 21)

Detailed reference viewed: 11 (2 ULg)
Peer Reviewed
See detail16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo
Kinet, Virginie; Castermans, Karolien; Blacher, Silvia ULg et al

Poster (2010, March)

Detailed reference viewed: 11 (0 ULg)